Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center

Articles

IO Therapy in mCRPC and Clinical Pearls

May 24th 2023

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.

Practical Application of PARP Inhibitors in Metastatic CRPC

May 24th 2023

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC: Advent of PARP Inhibitors

May 17th 2023

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

Overview of the Metastatic Castration-Resistant Prostate Cancer Treatment Paradigm

May 17th 2023

Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).

Novel Treatment Modalities in Metastatic Hormone-Sensitive Prostate Cancer

May 10th 2023

Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.

Educating Patients on Treatment Options in Metastatic HSPC

May 10th 2023

Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.

Metastatic Hormone-Sensitive Prostate Cancer: Data from TITAN and PEACE-1

May 3rd 2023

Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.

Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES

May 3rd 2023

Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.

Metastatic Hormone-Sensitive Prostate Cancer: Data From ARASENS and ARANOTE

April 26th 2023

A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.

mHSPC: Use of Triplet Therapy

April 26th 2023

Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.

Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

April 19th 2023

A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.

Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate Cancer

April 19th 2023

Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.

Optimizing Care for Patients With Non-metastatic CRPC

April 12th 2023

Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.

Non-metastatic Castration-Resistant Prostate Cancer: Patient Monitoring Strategies

April 12th 2023

Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.

Importance of Quality of Life When Choosing Therapy for nmCRPC

April 5th 2023

A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.

AR Inhibitors in nmCRPC: Real-World Data

April 5th 2023

Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.

nmCRPC: Clinical Trial Data on AR Inhibitors

March 29th 2023

Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.

Goals of Treatment for Non-metastatic Castration-Resistant Prostate Cancer

March 29th 2023

Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Key Unmet Needs in Prostate Cancer Management

March 22nd 2023

Before centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.

Dr. Posadas Discusses Cabozantinib in Prostate Cancer

June 11th 2014

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer(mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.